The AI platform discovers patterns in patient movement that expert clinicians felt were significant but couldn't objectively measure. This process of data-driven confirmation helps build trust and accelerates the adoption of AI tools by providing evidence for long-held clinical instincts, turning a subjective feeling into objective proof.
Effion Health's core technology was initially for an exoskeleton project. The company's pivotal shift to monitoring Duchenne muscular dystrophy occurred when a friend, whose son has the disease, recognized the sensors' gait analysis potential. This highlights how direct market feedback can redefine a company's entire mission.
In rare diseases with small patient pools, recruiting for clinical trials is a major challenge. Effion Health's highly sensitive digital biomarkers can detect therapeutic efficacy with fewer participants, potentially reducing the required number of patients by 30%, which saves significant time and money for pharmaceutical companies.
Rather than aiming directly for high-stakes clinical trials, Effion Health's go-to-market strategy begins with post-market, real-world evidence studies. This approach allows them to demonstrate their technology's value in a real-world setting, building a strong case for adoption in earlier, more critical drug development phases.
To overcome the "black box" problem in medical AI, Effion Health provides clinicians with a dashboard that reveals the specific parameters used to calculate its biomarker score. This transparency allows doctors to understand the AI's reasoning, fostering the trust required for confident clinical decision-making.
Traditional clinical assessments, like the six-minute walk test, are easily skewed by external factors such as patient fatigue. Effion Health's digital biomarker system can isolate and measure the underlying pathological movement patterns, providing a more sensitive and precise measurement of disease progression regardless of temporary conditions.